Immunopharmacological activity of perfluorotributylamine
Kovalev, I.E.; Rubtsova, E.R.; Podymova, N.G.; Konovalova, N.V.; Neugodova, T.P.
Farmakologiia i Toksikologiia 49(2): 28-31
1986
ISSN/ISBN: 0014-8318 PMID: 3709773 Document Number: 281686
It was shown in experiments on mice that the chemically inert compound perfluortributylamine has sufficiently expressed immunopharmacological activity. Its intraperitoneal administration causes a drop in the immune response of mice, immunized with sheep erythrocytes. These animals had a marked durable resistance to the soporific action of hexenal.
Document emailed within 1 workday
Related Documents
Urtizberea, M.; Latour, M.; Edelman, L.; Carcagne, J.; Armand, J.; Scherrmann, J.M. 1990: Immunopharmacological activity of monoclonal antidigitoxin Developments in Biological Standardization 71: 147-157Chanarat, P.; Chanarat, N.; Fujihara, M.; Nagumo, T. 1997: Immunopharmacological activity of polysaccharide from the pericarb of mangosteen garcinia: phagocytic intracellular killing activities Journal of the Medical Association of Thailand 80(Suppl 1): S149-S154
Giełdanowski, J.; Kowalczyk-Bronisz, S.H.; Błaszczyk, B. 1990: Immunopharmacological indices of piroxicam Archivum Immunologiae et Therapiae Experimentalis 38(3-4): 239-247
Dukor, P. 1978: Immunopharmacological control of inflammation Annals of the Royal College of Surgeons of England 60(3): 204-207
Ríos-Hernández, M.; Dos-Santos, N.J.; Silvia-Cardoso; Bello-Gárciga, J.L.; Pedroso, M. 1994: Immunopharmacological studies of beta-1,3-glucan Archives of Medical Research 25(2): 179-180
Matsuno, H.; Kitano, T.; Matsushita, I.; Tsuji, H.; Ochiai, H. 1993: Immunopharmacological evaluation of bucillamine in rheumatoid arthritis Drugs under Experimental and Clinical Research 19(5): 205-211
Florentin, I.; Chung, V.; Martinez, J.; Maral, J.; Le Garrec, Y.; Mathé, G. 1986: In vivo immunopharmacological properties of tuftsin (Thr-Lys-Pro-Arg) and some analogues Methods and Findings in Experimental and Clinical Pharmacology 8(2): 73-80
Rojo, J.M.; Barasoain, I.; Jorba, G.; Portolés, A. 1980: Immunopharmacological controls of indirect side-effects in antibiotherapy Archivos de Farmacologia y Toxicologia 6(2): 107-118
Takeshita, K.; Fukazawa, I.; Nakaike, S.; Kameo, K.; Tomisawa, K.; Otomo, S.; Aihara, H. 1988: Immunopharmacological studies of new 3-benzoyl-4-mercaptobutyric acid derivatives. II. Immunosuppressive effects Drugs under Experimental and Clinical Research 14(5): 311-318
Yanagihara, Y.; Koda, A. 1979: Immunopharmacological study of buckwheat hypersensitivity (II). Effect of dialysate on antibody formation Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 75(7): 721-730
Kowalczyk-Bronisz, S.H.; Mojsiejewska, D.; Pomorski, J. 1991: Synthesis and immunopharmacological analysis of selected derivatives of N,N'-bis-/3-aziridine/butanoylalkylenediamines and imides of 3-aziridinesuccinic acid. i Archivum Immunologiae et Therapiae Experimentalis 39(3): 261-269
Kuz'min, S.N.; Pershin, B.B.; Medvedev, V.I.; Filatov, N.N.; Gimushina, V.D. 1994: Validation of the choice of the optimal immunopharmacological schemes for performing mass antigen-nonspecific immunoprophylactic measures Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 6: 46-48
Pandey, B.L.; Das, P.K. 1988: Immunopharmacological studies on Picrorhiza kurroa Royle-ex-Benth. Part III: Adrenergic mechanisms of anti-inflammatory action Indian Journal of Physiology and Pharmacology 32(2): 120-125
Yanagihara, Y.; Abe, T.; Kuroda, T.; Shida, T. 1988: Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 5th communication: effects on immunological reactions in mice and humans Arzneimittel-Forschung 38(1): 88-92
Kowalczyk-Bronisz, S.H.; Zabska, R. 1986: Studies on the derivatives of aziridine. I. synthesis and immunopharmacological analysis of amides of alpha-aziridinyl- beta-/p-chlorobenzoyl/-propionic acid Archivum Immunologiae et Therapiae Experimentalis 34(3): 333-350
Yanagihara, Y.; Abe, T.; Edanami, K.; Agata, M.; Kuroda, T.; Shida, T. 1988: Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 1st communication: effects on type I to type IV allergic reactions in animal models Arzneimittel-Forschung 38(1): 70-74
Yanagihara, Y.; Shida, T. 1986: Immunopharmacological actions of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid. Effects on type i hypersensitivity reactions in human leukocytes and in human and monkey lungs Arzneimittel-Forschung 36(11): 1627-1631
Ihle, J.N.; Keller, J.; Oroszlan, S.; Henderson, L.E.; Copeland, T.D.; Fitch, F.; Prystowsky, M.B.; Goldwasser, E.; Schrader, J.W.; Palaszynski, E.; Dy, M.; Lebel, B. 1983: Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity Journal of Immunology 131(1): 282-287
Gatzounis, R.; Schrooten, M.G.S.; Crombez, G.; Vlaeyen, J.W.S. 2018: Activity interruptions by pain impair activity resumption, but not more than activity interruptions by other stimuli: an experimental investigation Pain 159(2): 351-358
Vitali, C.; Bencivelli, W.; Isenberg, D.A.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; Neri, R.; Bombardieri, S. 1992: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE Clinical and Experimental Rheumatology 10(5): 541-547